ZEMAIRA (Alpha1-Proteinase Inhibitor) | Patient Website

Time 2021-01-11 06:03:01

Web Name: ZEMAIRA (Alpha1-Proteinase Inhibitor) | Patient Website

WebSite: http://www.zemaira.com

ID:163400

Keywords:

Proteinase,ZEMAIRA,Website,

Description:

Easing the burden of Alpha-1 therapy Improved reconstitution with the Mix2Vial Transfer Set ZEMAIRA offers convenience with our innovative Mix2Vial Transfer Set by reducing the risk of spillage and helping prevent vacuum loss during reconstitution. For any questions related to reconstitution, please contact your healthcare professional. Experienced CareZ Care Coordinators Comprehensive patient support from a single point of contact Assistance verifying coverage and financial support Worried about the cost of treatment? Save with the ZEMAIRA Signature SavingsSM renewable co-pay program Enroll in CareZ or call 1-866-ZEMAIRA (1-866-936-2472) Easing the burden of Alpha-1 therapy Mix2Vial Transfer Set Improved Reconstitution Comprehensive patient support from CareZ Care Coordinators Enroll in CareZ Worried about treatment cost? Save with ZEMAIRA Signature SavingsSM Alpha1-Proteinase Inhibitor (Human), ZEMAIRA is indicated to raise the plasma level of alpha1-proteinase inhibitor (A1-PI) in patients with A1-PI deficiency and related emphysema. The effect of this raised level on the frequency of pulmonary exacerbations and the progression of emphysema have not been established in clinical trials.ZEMAIRA may not be suitable for everyone; for example, people with known hypersensitivity to components used to make ZEMAIRA, those with a history of anaphylaxis or severe systemic response to A1-PI products, and those with certain IgA deficiencies. If you think any of these may apply to you, ask your doctor.Early signs of hypersensitivity reactions to ZEMAIRA include hives, rash, tightness of the chest, unusual breathing difficulty, wheezing, and feeling faint. Immediately discontinue use and consult with physician if such symptoms occur.In clinical studies, the following adverse reactions were reported in at least 5% of subjects receiving ZEMAIRA: headache, sinusitis, upper respiratory infection, bronchitis, fatigue, increased cough, fever, injection-site bleeding, nasal symptoms, sore throat, and swelled blood vessels.Because ZEMAIRA is made from human blood, the risk of transmitting infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent and its variant (vCJD), cannot be completely eliminated.Please see full prescribing information for ZEMAIRA.You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. ZEMAIRA is manufactured and distributed by CSL Behring LLC. Biotherapies for Life , ZEMAIRA , and CareZ are registered trademarks of CSL Behring LLC. ZEMAIRA QuickAccessSM, ZEMAIRA Signature SavingsSM, and CSL Behring AssuranceSM are all service marks of CSL Behring LLC. DNA1 Advanced Alpha-1 Screening is a trademark of CSL Behring LLC. 2021 CSL Behring LLC. The product information presented on this site is intended for US residents only.

TAGS:Proteinase ZEMAIRA Website 

<<< Thank you for your visit >>>

Learn about living with Alpha-1, along with the augmentation therapy and benefits that ZEMAIRA has to offer patients.

Hot Websites